Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | PHASE1 | RECRUITING | 117 | — | — | Feb 26, 2025 | Feb 1, 2029 | Apr 15, 2026 | 13 | United States, Spain |
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| Treatment Arm | EXPERIMENTAL | IM-1021 administered intravenously on a 21-day cycle, at a starting dose of 2 mg/kg. |
| Name | Type | Description |
|---|---|---|
| IM-1021 | BIOLOGICAL | IM-1021 is an antibody-drug conjugate |
Inclusion Criteria: 1. Informed consent signed by the participant prior to conducting study-specific procedures 2. ≥18 years of age 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 4. Histological or cytological diagnosis of: Part A: advanced B-cell lymphomas or sol...